Ferrocene modified analogues of imatinib and nilotinib as potent anti-cancer agents.

Philipova I, Mihaylova R, Momekov G, Angelova R, Stavrakov G

DOI: 10.1039/d3md00030c
Published: 2023 May 25
Container: RSC medicinal chemistry
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1039/d3md00030c,
  title = {Ferrocene modified analogues of imatinib and nilotinib as potent anti-cancer agents.},
  author = {Philipova I and Mihaylova R and Momekov G and Angelova R and Stavrakov G},
  year = {2023},
  journal = {RSC medicinal chemistry},
  doi = {10.1039/d3md00030c},
  url = {https://doi.org/10.1039/d3md00030c}
}

RIS

TY  - JOUR
TI  - Ferrocene modified analogues of imatinib and nilotinib as potent anti-cancer agents.
AU  - Philipova I
AU  - Mihaylova R
AU  - Momekov G
AU  - Angelova R
AU  - Stavrakov G
PY  - 2023
JO  - RSC medicinal chemistry
DO  - 10.1039/d3md00030c
UR  - https://doi.org/10.1039/d3md00030c
ER  -

APA

I, P., R, M., G, M., R, A., & G, S. (2023). Ferrocene modified analogues of imatinib and nilotinib as potent anti-cancer agents.. RSC medicinal chemistry. https://doi.org/10.1039/d3md00030c

Source records

pubmed · retrieved 2026-09-26T08:11:18.939Z